{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53380"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53380","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Programmable detection and modification of nucleic acids","abstract":"The development of nucleic acid diagnostic and therapeutic platforms had led to the creation of multiple CRISPR-enabled technologies that are being commercially pursued by many companies. Some diagnostic platforms have shown potential to be utilized at near point-of-care (POC) settings, but have crucial limitations in terms of shelf-stability and multiplexing capabilities. On the other hand, advances with CRISPR-based therapeutic platforms have led to the invention of multiple systems that can modularly modify genomic DNA, but these new systems lack adequate efficacy in therapeutic cell types that bear an intact Mismatch Repair (MMR) pathway. In this dissertation, nuclease-enabled diagnostic systems have been created that overcome existing limitations seen with molecular diagnostics, namely for sensing mutations and multiplexing on portable systems. These portable diagnostic platforms can provide attomolar sensitivity in as little as 15 minutes and can be rapidly programmed to detect a variety of nucleic acid markers. In addition, state-of-the-art CRISPR-enabled prime editing has been improved via engineering of circularized prime editing gRNAs (cpegRNAs) to increase the efficiency of genomic modifications. This cpegRNA platform can improve prime editing by ~35-fold in MMR-competent cells by exploiting the enhanced stability of circularized transcripts. Together, these novel molecular systems provide enhanced capabilities for nucleic acid diagnostics and CRISPR-enabled therapeutics.","abstract_html":"The development of nucleic acid diagnostic and therapeutic platforms had led to the creation of multiple CRISPR-enabled technologies that are being commercially pursued by many companies. Some diagnostic platforms have shown potential to be utilized at near point-of-care (POC) settings, but have crucial limitations in terms of shelf-stability and multiplexing capabilities. On the other hand, advances with CRISPR-based therapeutic platforms have led to the invention of multiple systems that can modularly modify genomic DNA, but these new systems lack adequate efficacy in therapeutic cell types that bear an intact Mismatch Repair (MMR) pathway. In this dissertation, nuclease-enabled diagnostic systems have been created that overcome existing limitations seen with molecular diagnostics, namely for sensing mutations and multiplexing on portable systems. These portable diagnostic platforms can provide attomolar sensitivity in as little as 15 minutes and can be rapidly programmed to detect a variety of nucleic acid markers. In addition, state-of-the-art CRISPR-enabled prime editing has been improved via engineering of circularized prime editing gRNAs (cpegRNAs) to increase the efficiency of genomic modifications. This cpegRNA platform can improve prime editing by ~35-fold in MMR-competent cells by exploiting the enhanced stability of circularized transcripts. Together, these novel molecular systems provide enhanced capabilities for nucleic acid diagnostics and CRISPR-enabled therapeutics.","abstract_has_math":false,"creators":["Babaei, Milad"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Molecular Biology, Cell Biology & Biochemistry","degree_department":null,"school":null,"contributors":[],"advisors":["Green, Alexander A."],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-19T02:42:12Z","subjects":["Bioengineering"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/53380","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53380","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53380","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Green, Alexander A."]},{"key":"dc:creator","label":"Author","values":["Babaei, Milad"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-07-29T13:52:32Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2028-07-09T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2025"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-07-09T16:15:32Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Molecular Biology, Cell Biology & Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Bioengineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53380"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2025"]},{"key":"dc:description.abstract","label":"Abstract","values":["The development of nucleic acid diagnostic and therapeutic platforms had led to the creation of multiple CRISPR-enabled technologies that are being commercially pursued by many companies. Some diagnostic platforms have shown potential to be utilized at near point-of-care (POC) settings, but have crucial limitations in terms of shelf-stability and multiplexing capabilities. On the other hand, advances with CRISPR-based therapeutic platforms have led to the invention of multiple systems that can modularly modify genomic DNA, but these new systems lack adequate efficacy in therapeutic cell types that bear an intact Mismatch Repair (MMR) pathway. In this dissertation, nuclease-enabled diagnostic systems have been created that overcome existing limitations seen with molecular diagnostics, namely for sensing mutations and multiplexing on portable systems. These portable diagnostic platforms can provide attomolar sensitivity in as little as 15 minutes and can be rapidly programmed to detect a variety of nucleic acid markers. In addition, state-of-the-art CRISPR-enabled prime editing has been improved via engineering of circularized prime editing gRNAs (cpegRNAs) to increase the efficiency of genomic modifications. This cpegRNA platform can improve prime editing by ~35-fold in MMR-competent cells by exploiting the enhanced stability of circularized transcripts. Together, these novel molecular systems provide enhanced capabilities for nucleic acid diagnostics and CRISPR-enabled therapeutics."]},{"key":"dc:title","label":"Title","values":["Programmable detection and modification of nucleic acids"]}]}],"canonical_facts":{"dc:contributor.advisor":["Green, Alexander A."],"dc:creator":["Babaei, Milad"],"dc:date.accessioned":["2026-07-29T13:52:32Z"],"dc:date.embargo":["2028-07-09T00:00:00Z"],"dc:date.issued":["2025"],"dc:date.updated":["2026-07-09T16:15:32Z"],"dc:description":["2025"],"dc:description.abstract":["The development of nucleic acid diagnostic and therapeutic platforms had led to the creation of multiple CRISPR-enabled technologies that are being commercially pursued by many companies. Some diagnostic platforms have shown potential to be utilized at near point-of-care (POC) settings, but have crucial limitations in terms of shelf-stability and multiplexing capabilities. On the other hand, advances with CRISPR-based therapeutic platforms have led to the invention of multiple systems that can modularly modify genomic DNA, but these new systems lack adequate efficacy in therapeutic cell types that bear an intact Mismatch Repair (MMR) pathway. In this dissertation, nuclease-enabled diagnostic systems have been created that overcome existing limitations seen with molecular diagnostics, namely for sensing mutations and multiplexing on portable systems. These portable diagnostic platforms can provide attomolar sensitivity in as little as 15 minutes and can be rapidly programmed to detect a variety of nucleic acid markers. In addition, state-of-the-art CRISPR-enabled prime editing has been improved via engineering of circularized prime editing gRNAs (cpegRNAs) to increase the efficiency of genomic modifications. This cpegRNA platform can improve prime editing by ~35-fold in MMR-competent cells by exploiting the enhanced stability of circularized transcripts. Together, these novel molecular systems provide enhanced capabilities for nucleic acid diagnostics and CRISPR-enabled therapeutics."],"dc:identifier.uri":["https://hdl.handle.net/2144/53380"],"dc:language.iso":["en_US"],"dc:subject":["Bioengineering"],"dc:title":["Programmable detection and modification of nucleic acids"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Molecular Biology, Cell Biology & Biochemistry"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:42:12Z"}